LBA8_PRKEYNOTE-048: Phase III study of first-line pembrolizumab (P) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). (23rd October 2018) - Burtness, B; Harrington, K J; Greil, R; Soulières, D; Tahara, M; De Castro, G; Psyrri, A; Baste Rotllan, N; Neupane, P C; Bratland, Å; Fuereder, T; Hughes, B G M; et al.